Benzinga Pro data, Akebia Therapeutics (NASDAQ:AKBA) reported Q4 sales of $59.60 million. Earnings fell to a loss of $70.68 million, resulting in a 18.7% decrease from last quarter. In Q3, Akebia Therapeutics brought in $48.76 million in sales but lost $59.54 million in earnings.

What Is Return On Capital Employed?

Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q4, Akebia Therapeutics posted an ROCE of -0.92%.

It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.

For Akebia Therapeutics, a negative ROCE ratio of -0.92% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Analyst Predictions

Akebia Therapeutics reported Q4 earnings per share at $-0.4/share, which did not meet analyst predictions of $-0.33/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.